14.07.2021 – 13:00
Cellares Corporation
South San Francisco, Kalifornien (ots/PRNewswire)
Second industrial partner to enter into a strategic partnership with Cellares to advance a closed, automated and scalable cell therapy manufacturing system
Poseida Therapeutics provides insights into autologous and allogeneic CAR-T workflows, as well as new programs that include TCR-T, genetically modified NK cells, and other cell therapy manufacturing workflows
Cellares Corporation, a life sciences technology company developing a revolutionary automated approach to manufacturing cell therapies, announced today thatPoseida Therapeutics, Inc, a clinical-stage biopharmaceutical company using proprietary genetic engineering platform technologies to manufacture cell and gene therapeutics with the ability to cure, has joined its Early Access Partnership Program (EAPP). Poseida is the third organization to participate in Cellares EAPP after the industrial partnerPACT Pharma and the academic partnerFred Hutchinson Cancer Research Center.
Cellares initiated the EAPP in 2020 to give participants visibility and early access toCellares’ Cell Shuttle to enable a next-generation cell therapy manufacturing platform that enables closed, automated and scalable cell therapy production. By joining the program, Poseida is helping to advance the development, field of application and applicability of the Cell Shuttle by providing insights into and experience with manufacturing processes for a variety of autologous and allogeneic cell therapies.
“We are thrilled to have Poseida Therapeutics on board to expand the capabilities of our Cell Shuttle platform,” says Cellares co-founder and managing director Fabian Gerlinghaus. “Poseida’s tremendous expertise in the field of cell therapy, particularly in relation to the various therapeutic modalities, is a great asset to our development efforts. We believe that our work with Poseida will increase the adaptability of the Cell Shuttle for different cell therapy modalities, in particular CAR T cells, will demonstrate. ”
Poseida currently has two autologous CAR-T product candidates in the clinic, including P-BCMA-101 for patients with relapsed / refractory multiple myeloma and P-PSMA-101 for patients with metastatic castration-resistant prostate cancer. The company, which went public in July 2020, also has commercial versions of both therapies under development and is researching TCR-T, Anti-C-Kit-CAR-T, induced pluripotent stem cells (iPSCs) and genetically modified hematopoietic stem cells (HSCs) and NK cells. Immunotherapy pioneer and respected oncologist Carl June, MD, a consultant to Cellares who helped develop the Cell Shuttle, recently joined Poseida’s Scientific Advisory Board for Immuno-Oncology.
“The flexibility of the Cell Shuttle fits in with the breadth of approaches we are developing at Poseida,” said Kerry Ingalls, chief operating officer at Poseida. “For our entire cell therapy portfolio, an automated production system should be able to reliably produce a range of autologous and allogeneic CAR-T therapies for both solid and hematological cancers, both for research and large-scale clinical applications Studies and eventually for commercial applications. By joining forces with Cellares, we believe we can leverage the capabilities of the Cell Shuttle to support our overall manufacturing strategy and advance cell therapy manufacturing. ”
As part of Cellares’ EAPP, Poseida will evaluate the Cell Shuttle prototypes and provide data and written feedback on function and performance. This includes user studies that evaluate the hardware and software of the Cell Shuttle, the product requirements, the approval criteria and the process flows in order to ensure the marketability of the product.
Information on the Cell Shuttle
Cell Shuttle is an automated and self-contained solution for the entire manufacturing process (end-to-end) that is flexible and scalable and is intended to enable customers to carry out exactly the processes that have been defined for their cell therapy. Compared to currently available methods for the production of cell therapies, this next-generation platform enables a process error rate that is three times lower and it can simultaneously produce more than 10 patient doses, which increases the scalability of production by a considerable order of magnitude. This reduces the manufacturing costs per patient for most processes by up to 70 percent.
About Cellares Corporation
Cellares is shaping the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. The company is developing a unique solution to overcome the limitations of making cell therapies that are more affordable and widely available for patients in need. With Cellares’ proprietary platform – Cell Shuttle – biopharmaceutical companies, academic research centers and CDMOs no longer have to compromise by choosing either a semi-automated production platform that lacks workflow flexibility or one that offers customization but doesn’t the end-to-end automation required for large-scale production. The company is headquartered in South San Francisco, California. For more information, see: www.cellares.com.
Press contact:
[email protected]
to business development:
[email protected]
Photos – https://mma.prnewswire.com/media/1572439/Cellares.jpg
Logo – https://mma.prnewswire.com/media/1503684/Cellares_Logo.jpg
– .
